Risk factors for sorafenib-induced high-grade skin rash in Japanese patients with advanced renal cell carcinoma

Anti-Cancer Drugs

Volumn 24, Issue 3, 2013, Pages 310-314

  Tsuchiya, Norihiko ^a   Narita, Shintaro ^a   Inoue, Takamitsu ^a   Hasunuma, Naoko ^a   Numakura, Kazuyuki ^a   Horikawa, Yohei ^a   Satoh, Shigeru ^a   Notoya, Takeshi ^b   Fujishima, Naohito ^b   Hatakeyama, Shingo ^c   Ohyama, Chikara ^c   Habuchi, Tomonori ^a  

^a AKITA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b AKITA UNIVERSITY HOSPITAL   (Japan)

^c HIROSAKI UNIVERSITY   (Japan)

Author keywords

erythema multiforme; human leukocyte antigen; polymorphism; renal cell carcinoma; skin rash; sorafenib

Indexed keywords

ABC TRANSPORTER; ADENOSINE TRIPHOSPHATE BINDING CASETTE SUBFAMILY C MEMBER 2; ALPHA INTERFERON; CYTOCHROME P450 3A5; GLUCURONOSYLTRANSFERASE 1A1; HLA A24 ANTIGEN; INTERLEUKIN 2; MULTIDRUG RESISTANCE PROTEIN 1; SORAFENIB; SUNITINIB; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; ANTIANGIOGENIC THERAPY; ARTICLE; BODY SURFACE; BODY WEIGHT; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DOSE RESPONSE; DRUG ERUPTION; DRUG WITHDRAWAL; FEMALE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; HLA TYPING; HUMAN; INCIDENCE; JAPANESE; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; SEX DIFFERENCE;

AGED; ANTINEOPLASTIC AGENTS; ASIAN CONTINENTAL ANCESTRY GROUP; CARCINOMA, RENAL CELL; CYTOCHROME P-450 CYP3A; DOSE-RESPONSE RELATIONSHIP, DRUG; EXANTHEMA; FEMALE; GLUCURONOSYLTRANSFERASE; HLA-A24 ANTIGEN; HUMANS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; NIACINAMIDE; P-GLYCOPROTEIN; PHENYLUREA COMPOUNDS; RETROSPECTIVE STUDIES;

EID: 84873360042     PISSN: 09594973     EISSN: 14735741     Source Type: Journal    
DOI: 10.1097/CAD.0b013e32835c401c     Document Type: Article

References (19)

1. Nexavar. Full prescribing information. Available at: Http://www. accessdata.fda. gov/drugsatfda-docs/label/2011/021923s011lbl.pdf. [Accessed 21 November 2012
2. Kodaira M, Takahashi S, Takeuchi K, Yuasa T, Saotome T, Yonese J, et al. Sorafenib-induced erythema multiforme for metastatic renal cell carcinoma. Ann Oncol 2010; 21:1563-1565
3. Bilac C, Muezzinoglu T, Ermertcan AT, Kayhan TC, Temeltas G, Ozturkcan S, et al. Sorafenib-induced erythema multiforme in metastatic renal cell carcinoma. Cutan Ocul Toxicol 2009; 28:90-92
4. Feltes RA, Feito Rodriguez M, Gonzalez-Beato MJ. Erythema multiforme induced by sorafenib. Clin Exp Dermatol 2009; 34:368-369
5. Lonjou C, Borot N, Sekula P, Ledger N, Thomas L, Halevy S, et al. A European study of HLA-B in Stevens-Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs. Pharmacogenet Genomics 2008; 18:99-107
6. Chung WH, Hung SI, Hong HS, Hsih MS, Yang LC, Ho HC, et al. Medical genetics: A marker for Stevens-Johnson syndrome. Nature 2004; 428:486
7. Tsuchiya N, Satoh S, Tada H, Li Z, Ohyama C, Sato K, et al. Influence of CYP3A5 and MDR1 (ABCB1) polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients. Transplantation 2004; 78: 1182-1187
8. Naesens M, Kuypers DR, Verbeke K, Vanrenterghem Y. Multidrug resistance protein 2 genetic polymorphisms influence mycophenolic acid exposure in renal allograft recipients. Transplantation 2006; 82:1074-1084
9. Ando Y, Saka H, Ando M, Sawa T, Muro K, Ueoka H, et al. Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: A pharmacogenetic analysis. Cancer Res 2000; 60:6921-6926
10. Ikeda M, Fujita T, Mii S, Tanabe K, Tabata K, Matsumoto K, et al. Erythema multiforme induced by sorafenib for metastatic renal cell carcinoma. Jpn J Clin Oncol 2012; 42:820-824
11. Lewin J, Farley-Loftus R, Pomeranz MK. Erythema multiforme-Like drug reaction to sorafenib. J Drugs Dermatol 2011; 10:1462-1463
12. Maddox JS, Kung EF, Petronic-Rosic V, Sethi A. Cutaneous drug eruptions induced by sorafenib: A case series. J Drugs Dermatol 2008; 7:891-893
13. MacGregor JL, Silvers DN, Grossman ME, Sherman WH. Sorafenibinduced erythema multiforme. J Am Acad Dermatol 2007; 56:527-528
14. Chung WH, Hung SI, Chen YT. Human leukocyte antigens and drug hypersensitivity. Curr Opin Allergy Clin Immunol 2007; 7:317-323
15. Lloberas N, Torras J, Cruzado JM, Andreu F, Oppenheimer F, Sanchez-Plumed J, et al. Influence of MRP2 on MPA pharmacokinetics in renal transplant recipients-results of the Pharmacogenomic Substudy within the symphony study. Nephrol Dial Transplant 2011; 26:3784-3793
16. Miura M, Satoh S, Inoue K, Kagaya H, Saito M, Inoue T, et al. Influence of SLCO1B1, 1B3, 2B1 and ABCC2 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients. Eur J Clin Pharmacol 2007; 63:1161-1169
17. Wei CY, Chung WH, Huang HW, Chen YT, Hung SI. Direct interaction between HLA-B and carbamazepine activates T cells in patients with Stevens-Johnson syndrome. J Allergy Clin Immunol 2012; 129: 1562-1569
18. Gonzalez-Galarza FF, Christmas S, Middleton D, Jones AR. Allele frequency net: A database and online repository for immune gene frequencies in worldwide populations. Nucleic Acids Res 2011; 39: 913-919
19. Zaccara G, Franciotta D, Perucca E. Idiosyncratic adverse reactions to antiepileptic drugs. Epilepsia 2007; 48:1223-1244